NCT07587268 Molecular Profiling for Risk Stratification in Appendiceal Cancer
| NCT ID | NCT07587268 |
| Status | Recruiting |
| Phase | — |
| Sponsor | City of Hope Medical Center |
| Condition | Appendiceal Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2026-05-01 |
| Primary Completion | 2027-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2026-05-01 with a primary completion date of 2027-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study investigates integrated epigenetic and epitranscriptomic features of appendiceal cancer using archived tumor tissue specimens from the same patient cohort. The study includes DNA methylation profiling and m6A epitranscriptomic profiling to define molecular subtypes, evaluate associations with clinicopathologic features, and develop molecular risk scores for prognostic stratification. The primary goal is to determine whether DNA methylation- and m6A-based molecular features can complement conventional histopathologic grading and improve risk stratification.
Eligibility Criteria
Inclusion Criteria: * Patients with histologically confirmed appendiceal adenocarcinoma or appendiceal cancer. * Availability of archived tumor tissue suitable for molecular profiling. * Availability of tissue for DNA methylation profiling, m6A epitranscriptomic profiling, or both. * Availability of relevant clinicopathologic data. * Availability of survival or follow-up information when applicable. * Age 18 years or older at diagnosis or tissue collection. Exclusion Criteria: * Insufficient tissue quantity or quality for molecular profiling. * Inadequate DNA or RNA quality for sequencing or molecular assay preparation. * Missing essential clinicopathologic information required for analysis. * Non-appendiceal primary tumor or metastatic tumor to the appendix from another primary site. * Patients who do not meet institutional review board or consent requirements, if applicable.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07587268 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Appendiceal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07587268 currently recruiting?
Yes, NCT07587268 is actively recruiting participants. Contact the research team at ajgoel@coh.org for enrollment information.
Where is the NCT07587268 trial being conducted?
This trial is being conducted at Duarte, United States.
Who is sponsoring the NCT07587268 clinical trial?
NCT07587268 is sponsored by City of Hope Medical Center. The trial plans to enroll 400 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.